What guidance did PDS Biotechnology's management provide for the next earnings period?

What is PDS Biotechnology's gross profit margin?

What is the market's earnings forecast for PDS Biotechnology next quarter?

What does PDS Biotechnology do and what are its main business segments?

What were the key takeaways from PDS Biotechnology's earnings call?

What factors drove the changes in PDS Biotechnology's revenue and profit?

What were the key takeaways from PDS Biotechnology’s earnings call?

What is PDS Biotechnology's latest dividend and current dividend yield?

- **Clinical Milestone**: VERSATILE-002 trial reports unprecedented 39.3-month MOS and 6.3-month PFS in HPV16-positive patients, supporting PDS0101's potential as a chemotherapy-free option.
- **Strategic Trial Amendment**: Seeking FDA approval to add PFS as primary endpoint in VERSATILE-003 to accelerate regulatory timeline.
- **Financial Efficiency**: 21% year-over-year reduction in operating expenses to $8.1 million, with $26.2 million cash balance post-equity financing.
- **Pipeline Momentum**: PDS01ADC colorectal cancer trial expands to Stage 2, while collaborations advance immunotherapy platforms.

**【CEO Summary Section】**
- **VERSATILE-002 Trial Results**: Final data showed median overall survival (MOS) of 39.3 months and progression-free survival (PFS) of 6.3 months in HPV16-positive head and neck cancer patients. A sensitivity analysis confirmed no negative impact of 9 censored patients on PFS or MOS.
- **VERSATILE-003 Protocol Amendment**: Proposed to add PFS as a surrogate primary endpoint alongside MOS to potentially accelerate trial readout. FDA meeting requested to discuss amendment.
- **Pipeline Progress**: PDS01ADC colorectal cancer cohort expanded to Stage 2 after positive Stage 1 results. Collaborations with NCI, MD Anderson, and Mayo Clinic support pipeline development.

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: Net loss of $9 million ($0.19 per share), down from $10.7 million ($0.29 per share) in Q3 2024. Operating expenses decreased 21% to $8.1 million due to lower R&D and G&A costs.
- **Cash Position**: $26.2 million as of September 30, 2025. Completed $5.3 million equity financing in October 2025.

**【Q&A Highlights】**
- **Patient Enrollment in VERSATILE-003**: Enrolled patients will continue treatment during the temporary pause. FDA discussions on new sample size and cost savings pending.
- **Control Arm PFS Assumptions**: Control arm PFS estimated at 3 months (based on KEYNOTE-048 and LEAP-010 studies), while PDS0101-treated patients achieved 6.3 months PFS in VERSATILE-002.
- **Competitive Landscape**: Focus on HPV16-positive head and neck cancer, a growing but underserved population (90% of oropharyngeal cancers are HPV16-positive).

PDSB

PDSB fundamentals

You can ask Aime